Stayble Therapeutics AB

Stayble Therapeutics is a Swedish life science company based in Gothenburg developing STA363, an injectable treatment for chronic low back pain caused by disc degeneration. STA363 (lactic acid) is injected into the intervertebral disc to induce a connective tissue transformation, permanently reducing pain by eliminating inflammatory substance leakage and stabilizing the disc. Phase 1b completed with established safety. Phase 2b-ready candidate, seeking a global partner.